
    
      This is a phase I, single center, randomized, double-blind and parallel group clinical trial.

      The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous
      injections of MW031 and Prolia® in healthy volunteers.

      The secondary objective are to assess the Clinical safety and immunogenicity similarity of
      single and subcutaneous injections of MW031 and Prolia® in healthy volunteers.

      At the same time, preliminary evaluate the pharmacodynamic similarity between MW031 and
      Prolia®.

      Subjects would receive a single 60mg（1mL）of MW031 or Prolia® through subcutaneous injection.
    
  